|
1
|
Ettinger DS, Akerley W, Borghaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK,
Govindan R, et al: Non-small cell lung cancer. J Natl Compr Canc
Netw. 10:1236–1271. 2012.PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Biesalski HK, de Mesquita B Bueno, Chesson
A, Chytil F, Grimble R, Hermus RJ, Köhrle J, Lotan R, Norpoth K,
Pastorino U and Thurnham D: European consensus statement on lung
cancer: Risk factors and prevention. Lung cancer panel. CA Cancer J
Clin. 48:167–176; discussion 164–166. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Secretan B, Straif K, Baan R, Grosse Y, El
Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C,
Galichet L, et al: A review of human carcinogens-Part E: Tobacco,
areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol.
10:1033–1034. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martínez-Sánchez JM, Fernández E, Fu M,
Gallus S, Martínez C, Sureda X, La Vecchia C and Clancy L: Smoking
behaviour, involuntary smoking, attitudes towards smoke-free
legislations, and tobacco control activities in the European Union.
PLoS One. 5:e138812010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fossella FV, DeVore R, Kerr RN, Crawford
J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, et al:
TAX Non-Small-Cell Lung Cancer Study Group: Randomized phase III
trial of docetaxel versus vinorelbine or ifosfamide in patients
with advanced non-small-cell lung cancer previously treated with
platinum-containing chemotherapy regimens. JCO. 18:2354–2362.
2000.
|
|
7
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Eastern
Cooperative Oncology Group: Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Avila MA, Berasain C, Sangro B and Prieto
J: New therapies for hepatocellular carcinoma. Oncogene.
25:3866–3884. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Llovet JM and Bruix J: Systematic review
of randomized trials for unresectable hepatocellular carcinoma:
Chemoembolization improves survival. Hepatology. 37:429–442. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hartmann TN, Burger JA, Glodek A, Fujii N
and Burger M: CXCR4 chemokine receptor and integrin signaling
co-operate in mediating adhesion and chemoresistance in small cell
lung cancer (SCLC) cells. Oncogene. 24:4462–4471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taron M, Rosell R, Felip E, Mendez P,
Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ
and Maestre J: BRCA1 mRNA expression levels as an indicator of
chemoresistance in lung cancer. Hum Mol Genet. 13:2443–2449. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma L, Wen S, Zhan Y, He Y, Liu X and Jiang
J: Anticancer effects of the Chinese medicine matrine on murine
hepatocellular carcinoma cells. Planta Med. 74:245–251. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yan Z, Jikai J, Xiaoshan L, et al:
Differentiation and apoptosis in K562 erythroleukemia cells induced
by matrine. Natural Med. 52:295–299. 1998.
|
|
14
|
Li CQ, Zhu YT, Zhang FX, Fu LC, Li XH,
Cheng Y and Li XY: Anti-HBV effect of liposome-encapsulated matrine
in vitro and in vivo. World J Gastroenterol. 11:426–428. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Zhu M, Shi R and Yang M: Radix
Sophorae flavescentis for chronic hepatitis B: A systematic review
of randomized trials. Am J Chin Med. 31:337–354. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang JP, Zhang M, Zhou JP, Liu FT, Zhou
B, Xie WF and Guo C: Antifibrotic effects of matrine on in vitro
and in vivo models of liver fibrosis in rats. Acta Pharmacol Sin.
22:183–186. 2001.PubMed/NCBI
|
|
17
|
Zhang LP, Jiang JK, Tam JW, Zhang Y, Liu
XS, Xu XR, Liu BZ and He YJ: Effects of matrine on proliferation
and differentiation in K-562 cells. Leuk Res. 25:793–800. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang YQ, Huang GS, Wang Z, Guo Y and
Zhang HY: Effects of matrine on the relative molecules expression
of proliferation and apoptosis in K562 cells. Zhongguo Yi Xue Ke
Xue Yuan Xue Bao. 23:333–336. 2001.(In Chinese). PubMed/NCBI
|
|
19
|
Wang Y, Peng C, Zhang G, Liu Y, Li H and
Shan J: Study on invasion and metastasis related factors in
differentiation of SMMC-7721 cells induced by matrine. Zhong Yao
Cai. 26:566–569. 2003.(In Chinese). PubMed/NCBI
|
|
20
|
Han Y, Zhang S, Wu J, Yu K, Zhang Y, Yin L
and Bi L: Matrine induces apoptosis of human multiple myeloma cells
via activation of the mitochondrial pathway. Leuk Lymphoma.
51:1337–1346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luo C, Zhu Y, Jiang T, Lu X, Zhang W, Jing
Q, Li J, Pang L, Chen K, Qiu F, et al: Matrine induced gastric
cancer MKN45 cells apoptosis via increasing pro-apoptotic molecules
of Bcl-2 family. Toxicology. 229:245–252. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang L, Wang T, Wen X, Wei Y, Peng X, Li
H and Wei L: Effect of matrine on HeLa cell adhesion and migration.
Eur J Pharmacol. 563:69–76. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hou G, Li N, Ma Y-H, Chen X-B, Wang X-F
and Luo S-X: Expression of Survivin and P-glycoprotein in non-small
cell lung cancer and their relationship with the effectiveness of
Matrine and pacilitaxel. Chin J Cancer Prev Treat. 20:350–353.
2013.
|
|
24
|
Liu B, Peng XC, Zheng XL, Wang J and Qin
YW: MiR-126 restoration down-regulate VEGF and inhibit the growth
of lung cancer cell lines in vitro and in vivo. Lung Cancer.
66:169–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Janmaat ML, Kruyt FA, Rodriguez JA and
Giaccone G: Response to epidermal growth factor receptor inhibitors
in non-small cell lung cancer cells: Limited antiproliferative
effects and absence of apoptosis associated with persistent
activity of extracellular signal-regulated kinase or Akt kinase
pathways. Clin Cancer Res. 9:2316–2326. 2003.PubMed/NCBI
|
|
26
|
Danielsen T, Hvidsten M, Stokke T, Solberg
K and Rofstad EK: Hypoxia induces p53 accumulation in the S-phase
and accumulation of hypophosphorylated retinoblastoma protein in
all cell cycle phases of human melanoma cells. Br J Cancer.
78:1547–1558. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takeuchi K, Choi YL, Togashi Y, Soda M,
Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, et al:
KIF5B-ALK, a novel fusion oncokinase identified by an
immunohistochemistry-based diagnostic system for ALK-positive lung
cancer. Clin Cancer Res. 15:3143–3149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu P, Dugoua JJ, Eyawo O and Mills EJ:
Traditional Chinese medicines in the treatment of hepatocellular
cancers: A systematic review and meta-analysis. J Exp Clin Cancer
Res. 28:1122009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Efferth T, Li PC, Konkimalla VS and Kaina
B: From traditional Chinese medicine to rational cancer therapy.
Trends Mol Med. 13:353–361. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Efferth T, Dunstan H, Sauerbrey A, Miyachi
H and Chitambar CR: The anti-malarial artesunate is also active
against cancer. Int J Oncol. 18:767–773. 2001.PubMed/NCBI
|
|
31
|
Efferth T, Sauerbrey A, Olbrich A, Gebhart
E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, et
al: Molecular modes of action of artesunate in tumor cell lines.
Mol Pharmacol. 64:382–394. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ooi LS, Wang H, Luk CW and Ooi VE:
Anticancer and antiviral activities of Youngia japonica (L.) DC
(Asteraceae, Compositae). J Ethnopharmacol. 94:117–122. 2004.
View Article : Google Scholar : PubMed/NCBI
|
